PCM
ALNY icon

Polymer Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Polymer Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$426K Buy
+1,415
New +$427K 0.06% 444
2026
Q1 		– Sell
-3,070
Closed -$1.22M – 819
2025
Q4 		$1.22M Buy
3,070
+2,262
+280% +$1M 0.13% 191
2025
Q3 		$368K Buy
+808
New +$329K 0.04% 517
2025
Q2 		– Sell
-961
Closed -$259K – 607
2025
Q1 		$259K Buy
+961
New +$247K 0.07% 390

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Polymer Capital Management's ALNY Position: Q2 2026 in Review

Polymer Capital Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 1,415 shares worth $426K. The stake represents 0.06% of the portfolio and ranks #444 among its holdings. This is a return to the name: Polymer Capital Management previously reported a position in ALNY as recently as Q4 2025.

Polymer Capital Management first reported a position in ALNY in Q1 2025 and has held it in 4 quarters since. The position peaked at $1.22M in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Polymer Capital Management held 1,415 shares of Alnylam Pharmaceuticals worth $426K as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Polymer Capital Management position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.06% of Polymer Capital Management's portfolio in Q2 2026, its #444 holding.
  • Polymer Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • Polymer Capital Management's Alnylam Pharmaceuticals position peaked at $1.22M in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Polymer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.